News
February 01, 2022

Icosagen Strengthens BD Team with Oliver Schub for Next Level Growth Stage: Stable CHO Cell Line Development and Therapeutic Protein Production


Icosagen Group has been steadily and strongly growing over the past years to more than 120 employees. We have built a world-wide reputation for therapeutic antibody discovery and recombinant antibody/protein production for our IVD, biotech, and pharma partners, based on our patented HybriFree and QMCF Technology Platforms. Recently, we successfully ventured even into the medical products world, with our Bioblock® anti-Covid19 nasal spray. 


With the overwhelming support of our biotech & pharma clients, who are taking their protein molecules into clinics, we are now very pleased to announce Icosagen’s expansion into the Large-Scale Therapeutic Protein Production and CDMO world with our IcoCell Platform for stable monoclonal CHO cell line development and in-house protein purification.
To do so, Icosagen has hired Dr. Oliver Schub to join our BD team, in order to support our coming expansion towards clinical therapeutic protein production services.
 
Oliver is a chemist by training with a PhD in biochemistry, a 4-year postdoc at University of Toronto in cell biology and an almost 20-year industry career in scientific BD, sales & marketing of therapeutic protein services in various internationally operating companies, including ProBioGen and Navigo Proteins. He combines expertise in biochemistry, protein chemistry, cell biology, structure-based drug design, cell line development, upstream and downstream processing, protein analytics, and activity assays. And he is globally very well connected in the biotech/biopharma word. “Oliver will help us to continue our expansion by plugging us into his global biopharma network and further increasing our visibility in US and European markets”, says Prof. Mart Ustav, Founder and CEO of Icosagen.

 
Oliver commented "I know and worked with the Icosagen team since years, and I felt since long that their absolutely competitive protein development expertise deserves to be more widely known among biologic drug-developing companies. I am thrilled to have become a true Icosageneer finally! After my first month of employment, I am awestruck by both the breadth and depth of their biologics’ capabilities, their commitment and growth prospects. Proud to help put this great team on the global map as mammalian biologics CHO Cell Line Development and CDMO expert 🚀!”

 

On behalf of the whole team, welcome onboard Oliver! Your know-how will be a great addition to our upcoming projects. We are excited to have you with us and look forward to working with you!



‹ Back to news